 |
 |
|
|
|  PubMed
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 December 1997 | Volume 127 Issue 11 | Pages 1013-1022
Purpose: The increasing incidence and biological heterogeneity of ductal carcinoma in situ (DCIS) of the breast have made the management of this entity challenging and controversial. This paper reviews data on the natural history of the disease and results obtained with various management approaches.
Data Sources: Computerized MEDLINE search of articles related to DCIS published since 1966.
Study Selection: Randomized trials were given higher value; however, because these were relatively scarce, retrospective studies and data published in abstract form were also included.
Data Extraction: The authors reviewed all sources critically. No formal statistical calculations were made.
Data Synthesis: The incidence of DCIS is increasing, and a greater proportion of diagnoses are being made in asymptomatic patients. No data from randomized trials compare mastectomy and breast-conserving therapy for the treatment of DCIS. A large randomized trial comparing lumpectomy with lumpectomy plus radiotherapy showed lumpectomy plus radiotherapy to be effective for management of this disease. The presence of comedo necrosis and surgical margin status are frequently used as predictors of subsequent recurrence, although this practice is controversial. The risk for in-breast recurrence at 5 years after lumpectomy and radiotherapy is approximately 8%. With more refined molecular analysis, the relation of DCIS to invasive breast cancer will be better defined.
Conclusions: Treatment strategies for DCIS have evolved, and lumpectomy followed by radiotherapy is an appropriate alternative for most patients. The use of lumpectomy alone in selected patients remains controversial.
Author and Article Information
From Mayo Clinic and Mayo Foundation, Rochester, Minnesota.
REVIEW
Ductal Carcinoma in Situ of the Breast
Requests for Reprints: Lynn C. Hartmann, MD, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.
Current Author Addresses: Drs. Fonseca and Hartmann: Department of Medical Oncology, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  C. R. Eheman, K. M. Shaw, A. B. Ryerson, J. W. Miller, U. A. Ajani, and M. C. White The Changing Incidence of In situ and Invasive Ductal and Lobular Breast Carcinomas: United States, 1999-2004 Cancer Epidemiol. Biomarkers Prev., June 1, 2009; 18(6): 1763 - 1769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Schernhammer and S. E. Hankinson Urinary Melatonin Levels and Postmenopausal Breast Cancer Risk in the Nurses' Health Study Cohort Cancer Epidemiol. Biomarkers Prev., January 1, 2009; 18(1): 74 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. Ernster, R. Ballard-Barbash, W. E. Barlow, Y. Zheng, D. L. Weaver, G. Cutter, B. C. Yankaskas, R. Rosenberg, P. A. Carney, K. Kerlikowske, et al. Detection of Ductal Carcinoma In Situ in Women Undergoing Screening Mammography J Natl Cancer Inst, October 16, 2002; 94(20): 1546 - 1554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Taplin, C. M. Rutter, C. Finder, M. T. Mandelson, F. Houn, and E. White Screening Mammography: Clinical Image Quality and the Risk of Interval Breast Cancer Am. J. Roentgenol., April 1, 2002; 178(4): 797 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Walter and K. E. Covinsky Cancer Screening in Elderly Patients: A Framework for Individualized Decision Making JAMA, June 6, 2001; 285(21): 2750 - 2756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Silverman, S. Woloshin, L. M. Schwartz, S. J. Byram, H. G. Welch, and B. Fischhoff Women's Views on Breast Cancer Risk and Screening Mammography: A Qualitative Interview Study Med Decis Making, May 1, 2001; 21(3): 231 - 240. [Abstract] [PDF]
|
|
|
|
 |
|
 M. H. Cohen, S. Hirschfeld, S. F. Honig, A. Ibrahim, J. R. Johnson, J. J. O'Leary, R. M. White, G. A. Williams, and R. Pazdur Drug Approval Summaries: Arsenic Trioxide, Tamoxifen Citrate, Anastrazole, Paclitaxel, Bexarotene Oncologist, February 1, 2001; 6(1): 4 - 11. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. Kopelovich, D. E. Henson, A. F. Gazdar, B. Dunn, S. Srivastava, G. J. Kelloff, and P. Greenwald Surrogate Anatomic/Functional Sites for Evaluating Cancer Risk: An Extension of the Field Effect Clin. Cancer Res., December 1, 1999; 5(12): 3899 - 3905. [Full Text] [PDF]
|
|
|
|
|
|
M. B. Barton, R. Harris, and S. W. Fletcher Does This Patient Have Breast Cancer?: The Screening Clinical Breast Examination: Should It Be Done? How? JAMA, October 6, 1999; 282(13): 1270 - 1280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Hartmann, D. J. Schaid, J. E. Woods, T. P. Crotty, J. L. Myers, P.G. Arnold, P. M. Petty, T. A. Sellers, J. L. Johnson, S. K. McDonnell, et al. Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer N. Engl. J. Med., January 14, 1999; 340(2): 77 - 84. [Abstract] [Full Text] [PDF]
|
|
